title: Decrease in triglyceride level by bezafibrate is related to reduction of recurrent coronary events: a Bezafibrate Infarction Prevention substudy.
abstract: BACKGROUND
  Fibrates were reported to be effective in reducing recurrent coronary events in coronary heart disease patients with elevated triglycerides. It is not known whether this effect is related to the extent of triglyceride reduction.
  
  
  METHODS
  Participants comprised 3090 coronary heart disease patients enrolled in the Bezafibrate Infarction Prevention study, which showed a nonsignificant reduction (9.4%; P=0.26) in fatal or nonfatal myocardial infarction and sudden death during a mean follow-up time of 6.2 years.
  
  
  RESULTS
  Significant reduction in triglyceride serum level was evident only among patients allocated to bezafibrate, ranging between 0.06 mmol/l (5 mg/dl) in the lowest decile of baseline triglycerides level and 0.68 mmol/l (60 mg/dl) in the highest baseline decile. The extent of triglyceride reduction with bezafibrate was significantly associated with the reduction of risk; relative risk reduction of 55% (hazards ratio: 0.45; 95% confidence interval: 0.24-0.84) was observed among patients with baseline triglycerides>or=2.26 mmol/l who reduced triglyceride level to >0.50 mmol/l (>44.3 mg/dl). In contrast, the risk of recurrent events among patients treated with bezafibrate and achieving less triglyceride reduction or failing to reduce triglyceride level was not significantly different from that of patients treated with placebo.
  
  
  CONCLUSIONS
  Bezafibrate treatment was associated with significant risk reduction among coronary heart disease patients with elevated triglyceride levels that substantially reduced their triglyceride level with treatment.
authors.affiliation: Cardiology Department, Rabin Medical Center, Petach-Tikva, Sackler School of Medicine, Tel-Aviv University, Israel.
authors.forename: Moti
authors.initials: M
authors.lastname: Haim
authors.forename: Michal
authors.initials: M
authors.lastname: Benderly
authors.forename: Valentina
authors.initials: V
authors.lastname: Boyko
authors.forename: Ilan
authors.initials: I
authors.lastname: Goldenberg
authors.forename: David
authors.initials: D
authors.lastname: Tanne
authors.forename: Alex
authors.initials: A
authors.lastname: Battler
authors.forename: Uri
authors.initials: U
authors.lastname: Goldbourt
authors.forename: Solomon
authors.initials: S
authors.lastname: Behar
mesh_terms: D000368:Aged; D001629:Bezafibrate / Q000494:pharmacology* / Q000627:therapeutic use; D002995:Clofibric Acid / Q000494:pharmacology* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D015228:Hypertriglyceridemia / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D018570:Risk Assessment; D012307:Risk Factors; D055502:Secondary Prevention; D014280:Triglycerides / Q000097:blood*
chemical_list: D000960:Hypolipidemic Agents; D014280:Triglycerides; D002995:Clofibric Acid; D001629:Bezafibrate